Abstract: A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[ (4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid methyl ester selectively into (2S)-2-[ (4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid having high chiral purity, using protease from Bacillus licheniformis. Converting the chirally pure acid into an amide results in Brivaracetam.

Abstract: A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid methyl ester selectively into (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid having high chiral purity, using protease from Bacillus licheniformis. Converting the chirally pure acid into amide results in Brivaracetam.

Abstract: A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising Hofmann rearrangement of (S)-3-(2-(chloroamino)-2-oxoethyl) hexanoic acid, followed by cyclization resulting in (R)-4-propyl-pyrrolidin-2-one which on condensation with bromo butyric acid or ester followed by reaction with ammonia results in Brivaracetam.

Abstract: A novel process for the preparation of L-threo-dihydroxyphenylserine (Droxidopa) is described. It comprises of enantioselective hydrolysis of racemic (DL)-threo-N-acetyl-3-(3,4-methylenedioxyphenyl)-serine using commercially available L-amino acylase from Aspergillus sp. (EC 3.5.1.14) in the presence of cobalt ions, to obtain (L)-threo-3-(3,4-methylenedioxyphenyl)-serine followed by dealkylation to obtain Droxidopa. Protecting the amino group of (L)-threo-3-(3,4-methylenedioxyphenyl)-serine using either benzyloxycarbonyl or phthaloyl group before dealkylation followed by deprotection of the amino group results in obtaining Droxidopa in high yields and purity.

Abstract: A novel process for the preparation of L-threo-dihydroxyphenylserine (Droxidopa) is described. It comprises of enantioselective hydrolysis of racemic (DL)-threo-N-acetyl-3-(3,4-methylenedioxyphenyl)-serine using commercially available L-amino acylase from Aspergillus sp. (EC 3.5.1.14) in the presence of cobalt ions, to obtain (L)-threo-3-(3,4-methylenedioxyphenyl)-serine followed by dealkylation to obtain Droxidopa. Protecting the amino group of (L)-threo-3-(3,4-methylenedioxyphenyl)-serine using either benzyloxycarbonyl or phthaloyl group before dealkylation followed by deprotection of the amino group results in obtaining Droxidopa in high yields and purity.

Abstract: A novelprocess for the preparation of N—[N-[3-(3-hydroxy-4-methoxyphenyl)-propyl]-L-?-aspartyl]-L-phenylalanine-1-methyl ester is described. It comprises, reacting isovanillin or its derivative with vinyl acetate followed by reductive condensation with L-[?-aspartyl]-L-phenylalanine-1-methyl ester.

Abstract: A novelprocess for the preparation of N—[N-[3-(3-hydroxy-4-methoxyphenyl)-propyl]-L-?-aspartyl]-L-phenylalanine-1-methyl ester is described. It comprises, reacting isovanillin or its derivative with vinyl acetate followed by reductive condensation with L-[?-aspartyl]-L-phenylalanine-1-methyl ester.

Abstract: A novel process for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide (Lacosamide) is described. It comprises reacting N-acetyl-D-serine methyl ester with benzylamine catalyzed by a non-nucleophilic base to obtain (R)-2-acetamido-2-N-benzyl-3-hydroxy propionamide followed by its methylation.

Abstract: The present invention provides a method for preparing colorless sucralose, wherein 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acetate containing colored impurities formed during chlorination of sucrose-6-acetate is treated with sodium hypochlorite, where sodium hypochlorite acts both as a decolorizing agent and as a reagent for the ester hydrolysis.

Abstract: Enantiomerically pure L-tert-leucine and D-tert-leucine were prepared from (DL)-tert-leucine by diastereomeric salt formation using dibenzoyl-d-tartaric acid as the resolving agent.

Abstract: Strontium ranelate is prepared by reacting dicyclohexylammonium ranelate with strontium halide in an anhydrous solvent. Strontium ranelate thus obtained will have less than 3% moisture content.

Abstract: Strontium ranelate is prepared by reacting dicyclohexylammonium ranelate with strontium halide in an anhydrous solvent. Strontium ranelate thus obtained will have less than 3% moisture content.

Abstract: This invention discloses a process for converting gabapentin acid salt to free gabapentin, where the salt is dissolved in an organic solvent in which both gabapentin acid salt and free gabapentin are soluble. The solution is treated with a powdered alkaline base to liberate free gabapentin which will remain in solution. The insoluble alkali salt of the acid is removed by filtration. From the filtrate free gabapentin is obtained either by adding anti-solvent or by extraction with water.

Abstract: The present invention provides a method for preparing colorless sucralose, wherein 4,1?,6?-trichloro-4,1?,6?-trideoxy-galacto sucrose-6- acetate containing colored impurities formed during chlorination of sucrose-6-acetate is treated with sodium hypochlorite, where sodium hypochlorite acts both as a decolorizing agent and as a reagent for the ester hydrolysis.

Abstract: Enantiomerically pure L-tert-leucine and D-tert-leucine were prepared from (DL)-tert-leucine by diastereomeric salt formation using dibenzoyl-d-tartaric acid as the resolving agent.

Abstract: This invention discloses a process for converting gabapentin acid salt to free gabapentin, where the salt is dissolved in an organic solvent in which both gabapentin acid salt and free gabapentin are soluble. The solution is treated with a powdered alkaline base to liberate free gabapentin which will remain in solution. The insoluble alkali salt of the acid is removed by filtration. From the filtrate free gabapentin is obtained either by adding anti-solvent or by extraction with water.

Abstract: This invention discloses Strontium Ranelate polymorph, designated as Form A, having a characteristic powdered x-ray diffraction pattern and infrared spectrum with a water content of about 1.5 to 2.5% and a process for its preparation.